Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alkermes plc - Ordinary Shares (NQ:ALKS)

35.08 +0.31 (+0.89%)
Streaming Delayed Price Updated: 3:41 PM EDT, Apr 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Alkermes plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Lilly’s $7.8 Billion Centessa Bet: Inside the Race to Dominate the Sleep Market’s ‘Orexin Gold Rush’
On March 31, 2026, Eli Lilly and Company (NYSE:LLY) sent shockwaves through the biotechnology sector by announcing a definitive agreement to acquire Centessa Pharmaceuticals (Nasdaq:CNTA) for a total... 
Via MarketMinute
News headline image
The Orexin Gold Rush: Deep Dive into Eli Lilly’s $7.8 Billion Acquisition of Centessa Pharmaceuticals
Today, March 31, 2026, the biotechnology landscape has been fundamentally reshaped. Eli Lilly and Company (NYSE: LLY) has officially announced a definitive agreement to acquire Centessa Pharmaceuticals... 
Via Finterra
Topics Economy Initial Public Offering Intellectual Property
Alkermes PLC (NASDAQ:ALKS) Reports Strong Q4 Earnings Beat Amid Muted Market Reaction ↗
Via Chartmill
Topics Earnings
Race For Avadel Heats Up: Alkermes Raises Offer To Secure $2.37B Deal After Lundbeck Challenge ↗
Via Stocktwits
News headline image
Earnings Scheduled For October 28, 2025 ↗
 
Via Benzinga
News headline image
Preview: Alkermes's Earnings ↗
 
Via Benzinga
News headline image
Alkermes (ALKS) Q4 2025 Earnings Call Transcript ↗
Alkermes (ALKS) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer ↗
Agios Pharmaceuticals develops therapies for rare blood disorders, anchored by its PYRUKYND franchise and early-stage clinical programs. 
Via The Motley Fool
News headline image
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake ↗
Viridian Therapeutics develops monoclonal antibody therapies targeting rare diseases, with a focus on thyroid eye disease treatments. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million ↗
Spyre Therapeutics develops preclinical monoclonal antibody therapies targeting inflammatory bowel disease and related conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50% ↗
Centessa Pharmaceuticals develops clinical-stage therapies for rare and serious diseases, leveraging a portfolio approach in biopharma. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% ↗
Nuvalent develops targeted cancer therapies, advancing clinical candidates for patients with limited treatment options in oncology. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Lundbeck's Higher Buyout Proposal Challenges Alkermes' Pending $2 Billion Avadel Deal ↗
Avadel reviews Lundbeck's unsolicited $23 offer while maintaining its agreement with Alkermes as its board evaluates whether the new proposal could be superior. 
Via Benzinga
News headline image
Avadel Surges 20% On Lundbeck's Surprise Alkermes-Topping Bid ↗
A new bidding war could kick off in biotech with Avadel Pharmaceuticals at the center. 
Via Investor's Business Daily
News headline image
Avadel Gets Acquisition Proposal From Lundbeck Weeks After Inking Agreement With Alkermes ↗
Avadel’s board of directors is of the opinion that the fresh proposal would reasonably be expected to be considered superior to the company’s existing agreement with Alkermes. 
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Alkermes Eyes Global Phase 3 Trial After Encouraging Data From Sleep Disorder Study ↗
Alkermes' alixorexton met key goals in a phase 2 study for narcolepsy type 2, showing significant improvements in wakefulness and sleepiness scores. 
Via Benzinga
News headline image
This Alkermes Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Tuesday ↗
 
Via Benzinga
News headline image
ALKERMES PLC (NASDAQ:ALKS) Q3 2025 Earnings Beat Estimates and Drive Stock Surge ↗
Alkermes (ALKS) Q3 2025 earnings crush estimates with a 58% EPS beat and $394.2M revenue. The company raises its full-year 2025 financial guidance. 
Via Chartmill
Topics Earnings
News headline image
Deal Dispatch: From Four Roses Bourbon To Quantum Stakes, Here Are This Week's Sector Shake Ups ↗
Four Roses, Six Flags, and Trump's potential Quantum investments: This week's deal activity involves big bets across various sectors. 
Via Benzinga
Topics Government
News headline image
Breaking Down Alkermes: 8 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
Alkermes Strikes $2.1 Billion Avadel Deal, Gains Access To Narcolepsy Drug Lumryz ↗
Alkermes agrees to acquire Avadel for $2.1 billion, adding the successful Lumryz drug and accelerating entry into sleep medicine. Jazz litigation settled. 
Via Benzinga
News headline image
Avadel Pharmaceuticals Soars as Alkermes Announces $2.1 Billion Acquisition
DUBLIN, IRELAND – October 22, 2025 – Avadel Pharmaceuticals (NASDAQ: AVDL) shareholders are celebrating today as Alkermes plc (NASDAQ: ALKS) announced a definitive agreement to acquire the company for... 
Via MarketMinute
Topics Intellectual Property
News headline image
Avadel Jumps On $2.1 Billion Takeover Deal. But Buyer, Alkermes, Dives. ↗
The companies are both working in the sleep space, focusing on excessive daytime sleepiness. 
Via Investor's Business Daily
News headline image
Avadel Stock Rises After Acquisition Offer By Alkermes ↗
Alkermes will buy Avadel for up to $20 per share. 
Via Stocktwits
News headline image
9 Analysts Assess Alkermes: What You Need To Know ↗
Analysts' ratings for Alkermes (NASDAQ: ALKS) over the last quarter vary from bullish to bearish, as provided by 9 analysts. The following table encapsulates their recent ratings, offering a glimpse... 
Via Benzinga
News headline image
This Ciena Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings... 
Via Benzinga
News headline image
Deep Dive Into Alkermes Stock: Analyst Perspectives (7 Ratings) ↗
 
Via Benzinga
News headline image
Macy's Increases FY2025 Outlook, Joins REV Group, HealthEquity, Alphabet and Wellness And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
This Unisys Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.